LONG BEACH, Calif.--(BUSINESS WIRE)--Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported first quarter 2024 GAAP earnings per diluted share of $5.17 and adjusted earnings per diluted share of $5.73. Financial results are summarized below:

加利福尼亚州长滩市——（商业新闻短讯）——Molina Healthcare，Inc.（纽约证券交易所代码：MOH）（“公司”）今天公布2024年第一季度GAAP摊薄每股收益为5.17美元，调整后摊薄每股收益为5.73美元。财务结果总结如下：

Three months ended

截至三个月

March 31,

3月31日，

2024

2024

2023

2023

(In millions, except per-share results)

（单位：百万，每股业绩除外）

Premium Revenue

保费收入

$9,504

$9,504

$7,885

$7,885

Total Revenue

总收入

$9,931

$9,931

$8,149

$8,149

GAAP:

GAAP：

Net Income

净收入

$301

$301

$321

$321

EPS – Diluted

每股收益-稀释

$5.17

$5.17

$5.52

$5.52

Medical Care Ratio (MCR)

医疗保健比率（MCR）

88.5%

88.5%

87.1%

87.1%

G&A Ratio

一般资产负债率

7.2%

7.2%

7.2%

7.2%

After-tax Margin

税后利润率

3.0%

3.0%

3.9%

3.9%

Adjusted:

调整后：

Net Income

净收入

$334

$334

$337

$337

EPS – Diluted

每股收益-稀释

$5.73

$5.73

$5.81

$5.81

G&A Ratio

一般资产负债率

7.1%

7.1%

7.2%

7.2%

After-tax Margin

税后利润率

3.4%

3.4%

4.1%

4.1%

See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.

请参阅本版本末尾未经审计的非公认会计准则财务指标的对账。

Quarter Highlights

季度亮点

As of March 31, 2024, the Company served approximately 5.7 million members, an increase of 9% compared to March 31, 2023.

截至2024年3月31日，该公司为约570万会员提供服务，与2023年3月31日相比增长了9%。

Premium revenue was approximately $9.5 billion for the first quarter of 2024, an increase of 21% year over year.

2024年第一季度保费收入约为95亿美元，同比增长21%。

GAAP net income was $5.17 per diluted share for the first quarter of 2024, a decrease of 6% year over year.

2024年第一季度，GAAP净收入为摊薄每股5.17美元，同比下降6%。

Adjusted net income was $5.73 per diluted share for the first quarter of 2024, a decrease of 1% year over year.

2024年第一季度，调整后的净收入为摊薄每股5.73美元，同比下降1%。

The Company reaffirmed its full year 2024 guidance with expected premium revenue of approximately $38 billion and adjusted earnings of at least $23.50 per diluted share.

该公司重申了2024年全年的指导方针，预计保费收入约为380亿美元，调整后每股摊薄收益至少为23.50美元。

“We are very pleased with our first quarter performance,” said Joseph Zubretsky, President and Chief Executive Officer. “We delivered strong financial performance supported by excellent operating metrics across our business, while sustaining profitable growth consistent with our long-term targets.”

总裁兼首席执行官约瑟夫·祖布雷茨基（JosephZubretsky）表示：“我们对第一季度的表现非常满意。”。“我们通过出色的业务运营指标实现了强劲的财务业绩，同时保持了与长期目标一致的盈利增长。”

Premium Revenue

保费收入

Premium revenue was approximately $9.5 billion for the first quarter of 2024, an increase of 21% year over year. The higher premium revenue reflects new contract wins, acquisitions, and growth in the current footprint, partially offset by Medicaid redeterminations.

2024年第一季度保费收入约为95亿美元，同比增长21%。较高的保费收入反映了新合同的成功、收购和当前足迹的增长，部分被医疗补助的重新终止所抵消。

Net Income

净收入

GAAP net income for the first quarter of 2024 was $5.17 per diluted share, a decrease of 6% year over year. Adjusted net income for the first quarter of 2024 was $5.73 per diluted share, a decrease of 1% year over year. The year over year decrease in earnings per share reflects a shift in the quarterly earnings pattern based on the significant increase in new business in 2024..

2024年第一季度的GAAP净收入为摊薄每股5.17美元，同比下降6%。2024年第一季度调整后的净收入为稀释每股5.73美元，同比下降1%。每股收益的同比下降反映了基于2024年新业务大幅增加的季度收益模式的转变。。

Medical Care Ratio (MCR)

医疗保健比率（MCR）

The consolidated MCR for the first quarter of 2024 was 88.5%, reflecting changes in member mix due to growth across all segments and continued, strong medical cost management, and is in line with the Company’s expectation.

2024年第一季度的综合MCR为88.5%，反映了由于所有部门的增长以及持续的强大医疗成本管理，成员结构发生了变化，符合公司的预期。

The Medicaid MCR for the first quarter of 2024 was 89.7%, in line with the Company’s expectation and normal quarter to quarter trend fluctuations within our guidance. The new store additions in California and Nebraska, as well as Iowa and the My Choice Wisconsin acquisition in late-2023, drove a higher reported MCR in the first quarter of 2024..

2024年第一季度的医疗补助MCR为89.7%，符合公司的预期，并且在我们的指导下，季度间趋势波动正常。2023年末，加利福尼亚州和内布拉斯加州以及爱荷华州新增门店，以及My Choice Wisconsin收购案，推动了2024年第一季度MCR的增长。。

The Medicare MCR for the first quarter of 2024 was 88.7%, in line with the Company’s expectations. Utilization in the legacy portfolio was consistent with the second half of 2023, but was offset by operational improvements and benefit adjustments.

2024年第一季度的医疗保险MCR为88.7%，符合公司的预期。遗留投资组合的利用率与2023年下半年一致，但被运营改进和收益调整所抵消。

The Marketplace MCR for the first quarter of 2024 was 73.3%, reflecting the Company’s pricing strategy and seasonality.

2024年第一季度的市场MCR为73.3%，反映了公司的定价策略和季节性。

General and Administrative Expense Ratio

一般和管理费用比率

The G&A ratio and the adjusted G&A ratio for the first quarter of 2024 was 7.2% and 7.1%, respectively.

2024年第一季度的一般资产负债率和调整后的一般资产负债率分别为7.2%和7.1%。

Balance Sheet

资产负债表

Cash and investments at the parent company were $194 million as of March 31, 2024 compared to $742 million as of December 31, 2023.

截至2024年3月31日，母公司的现金和投资为1.94亿美元，而截至2023年12月31日，母公司的现金和投资为7.42亿美元。

Days in claims payable at March 31, 2024 was 49.

2024年3月31日的应付索赔天数为49天。

Cash Flow

现金流

Operating cash flow for the three months ended March 31, 2024 was $214 million, compared to $916 million for the three months ended March 31, 2023. The decrease in 2024 cash flow was driven by the net impact of timing differences in government receivables and payables.

截至2024年3月31日的三个月营业现金流为2.14亿美元，而截至2023年3月31日的三个月营业现金流为9.16亿美元。2024年现金流的减少是由于政府应收账款和应付账款的时间差异产生的净影响。

2024 Guidance

2024年指南

Premium revenue for the full year is expected to be approximately $38 billion, an increase of approximately 17% from the full year 2023.

全年保费收入预计约380亿美元，比2023年全年增长约17%。

The Company expects its full year adjusted earnings per diluted share in 2024 to be at least $23.50, representing approximately 13% growth over the full year 2023. While the Company is experiencing underlying strength in its core business, its full year guidance is unchanged to account for any potential earnings headwind in the second half of the year from potential contract losses in Virginia and Florida..

该公司预计2024年全年调整后稀释每股收益至少为23.50美元，比2023年全年增长约13%。虽然该公司在其核心业务中正处于潜在优势，但其全年指导方针不变，以解释下半年弗吉尼亚州和佛罗里达州潜在合同损失带来的任何潜在收益逆风。。

Conference Call

电话会议

Management will host a conference call and webcast to discuss Molina Healthcare’s first quarter results at 8:00 a.m. Eastern Time on Thursday, April 25, 2024. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 0974846. A telephonic replay of the conference call will be available through Thursday, May 9, 2024, by dialing (877) 344-7529 and entering confirmation number 7039934.

管理层将于2024年4月25日（星期四）东部时间上午8:00主持电话会议和网络广播，讨论Molina Healthcare的第一季度业绩。交互式电话会议的电话号码是（877）883-0383，确认号码是0974846。通过拨打（877）344-7529并输入确认号码7039934，可以在2024年5月9日（星期四）之前通过电话重播会议通话。

A live audio broadcast of this conference call will be available on Molina Healthcare’s website, molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast..

此次电话会议的现场音频广播将在Molina Healthcare的网站molinahearchealthcare.com上提供。直播结束后约一小时，将提供为期30天的在线重播。。

About Molina Healthcare

关于Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit molinahealthcare.com.

财富500强公司Molina Healthcare，Inc.根据医疗补助和医疗保险计划以及通过州保险市场提供管理医疗服务。有关Molina Healthcare的更多信息，请访问molinahearchcare.com。

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

1995年私人证券诉讼改革法案下的安全港声明

This earnings release and the Company’s accompanying oral remarks contain forward-looking statements. The Company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

本收益公告和公司随附的口头评论包含前瞻性声明。公司打算将此类前瞻性陈述纳入1933年《证券法》第27A节和1934年《证券交易法》第21E节所载前瞻性陈述的安全港规定。

Forward-looking statements provide current expectations of future events based on certain assumptions, and all statements other than statements of historical fact contained in this earnings release and the Company’s accompanying oral remarks may be forward-looking statements. In some cases, you can identify forward-looking statements by words such as “guidance,” “future,” “anticipates,” “believes,” “embedded,” “estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” or the negative of these terms or other similar expressions.

前瞻性声明根据某些假设提供了对未来事件的当前预期，除本收益公告和公司随附口头评论中包含的历史事实声明外，所有声明都可能是前瞻性声明。在某些情况下，您可以通过“指导”，“未来”，“预期”，“相信”，“嵌入”，“估计”，“预期”，“增长”，“打算”，“计划”，“预测”，“项目”，“将”，“将”，“可能”，“可以”，“可能”等词语或这些术语或其他类似表达的否定词来识别前瞻性陈述。

Forward-looking statements contained in this earnings release include, but are not limited to, statements regarding its 2024 guidance and long-term targets, expected headwinds, and management’s plans and objectives for future operations and business strategy..

本收益公告中包含的前瞻性声明包括但不限于有关2024年指导和长期目标、预期阻力以及管理层未来运营和业务战略计划和目标的声明。。

Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2023, which is on file with the U.S.

由于许多已知和未知的风险和不确定性，实际结果可能会有很大差异。这些风险和不确定性在公司截至2023年12月31日的10-K表年度报告中的“前瞻性声明”和“风险因素”标题下进行了讨论，该报告已提交给美国。

Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including its Quarterly Report on Form 10-Q for the periods ended March 31, 2024, to be filed with the SEC..

美国证券交易委员会（“SEC”），以及公司向SEC提交的其他文件，包括截至2024年3月31日的10-Q表季度报告，将提交给SEC。。

These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements.

这些报告可以在公司网站的“投资者关系”选项卡或SEC网站SEC.gov上访问。鉴于这些风险和不确定性，公司不能保证其前瞻性声明将被证明是准确的，也不能保证其前瞻性声明预测或预期的任何其他结果或发展实际上会发生，公司警告投资者不要过度依赖这些声明。

All forward-looking statements in this release represent the Company’s judgment as of April 24, 2024, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations..

本版本中的所有前瞻性声明均代表公司截至2024年4月24日的判断，除法律另有要求外，公司不承担更新任何前瞻性声明以使其符合实际结果或预期变化的义务。。

MOLINA HEALTHCARE, INC.

MOLINA医疗保健公司。

UNAUDITED CONSOLIDATED STATEMENTS OF INCOME

未经审计的合并损益表

Three Months Ended

截至三个月

March 31,

3月31日，

2024

2024

2023

2023

(In millions, except per-share amounts)

（单位：百万，每股金额除外）

Revenue:

收入：

Premium revenue

保费收入

$

$

9,504

9,504

$

$

7,885

7,885

Premium tax revenue

保费税收

297

297

172

172

Investment income

投资收益

108

108

71

71

Other revenue

其他收入

22

22

21

21

Total revenue

总收入

9,931

9,931

8,149

8,149

Operating expenses:

营业费用：

Medical care costs

医疗保健费用

8,414

8,414

6,871

6,871

General and administrative expenses

一般和管理费用

711

711

591

591

Premium tax expenses

保费税费

297

297

172

172

Depreciation and amortization

折旧和摊销

45

45

44

44

Other

其他

38

38

16

16

Total operating expenses

营业费用合计

9,505

9,505

7,694

7,694

Operating income

营业收入

426

426

455

455

Interest expense

利息支出

27

27

28

28

Income before income tax expense

所得税前收入

399

399

427

427

Income tax expense

所得税费用

98

98

106

106

Net income

净收入

$

$

301

301

$

$

321

321

Net income per share – Diluted

每股净收入-摊薄

$

$

5.17

5.17

$

$

5.52

5.52

Diluted weighted average shares outstanding

已发行稀释加权平均股

58.3

58.3

58.0

58.0

MOLINA HEALTHCARE, INC.

MOLINA医疗保健公司。

CONSOLIDATED BALANCE SHEETS

合并资产负债表

March 31,

3月31日，

December 31,

12月31日，

2024

2024

2023

2023

Unaudited

未经审计

(Dollars in millions,

（百万美元，

except per-share amounts)

每股金额除外）

ASSETS

资产

Current assets:

流动资产：

Cash and cash equivalents

现金及现金等价物

$

$

4,513

4,513

$

$

4,848

4,848

Investments

投资

4,424

4,424

4,259

4,259

Receivables

应收账款

3,350

3,350

3,104

3,104

Prepaid expenses and other current assets

预付费用和其他流动资产

381

381

331

331

Total current assets

流动资产总额

12,668

12,668

12,542

12,542

Property, equipment, and capitalized software, net

财产、设备和资本化软件净值

295

295

270

270

Goodwill and intangible assets, net

商誉和无形资产净额

1,927

1,927

1,449

Restricted investments

限制性投资

261

261

261

261

Deferred income taxes, net

递延所得税净额

228

228

227

227

Other assets

其他资产

134

134

143

143

Total assets

总资产

$

$

15,513

15,513

$

$

14,892

14,892

LIABILITIES AND STOCKHOLDERS’ EQUITY

负债和股东权益

Current liabilities:

流动负债：

Medical claims and benefits payable

应付医疗索赔和福利

$

$

4,571

4,571

$

$

4,204

4,204

Amounts due government agencies

应付政府机构款项

2,501

2,501

2,294

2,294

Accounts payable, accrued liabilities and other

应付账款、应计负债和其他

1,114

1,114

1,252

1,252

Deferred revenue

递延收入

328

328

418

418

Total current liabilities

流动负债合计

8,514

8,514

8,168

8,168

Long-term debt

长期债务

2,180

2,180

2,180

2,180

Finance lease liabilities

融资租赁负债

202

202

205

205

Other long-term liabilities

其他长期负债

124

124

124

124

Total liabilities

负债总额

11,020

11,020

10,677

10,677

Stockholders’ equity:

股东权益：

Common stock, $0.001 par value, 150 million shares authorized; outstanding: 59 million shares at March 31, 2024, and 58 million at December 31, 2023

普通股，面值0.001美元，授权1.5亿股；流通股：2024年3月31日为5900万股，2023年12月31日为5800万股

—

—

—

—

Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding

优先股，面值0.001美元；2000万股授权股份，无已发行和流通股份

—

—

—

—

Additional paid-in capital

额外实收资本

390

390

410

410

Accumulated other comprehensive loss

累积其他综合损失

(85

(85

)

)

(82

(82

)

)

Retained earnings

留存收益

4,188

4,188

3,887

3,887

Total stockholders’ equity

股东权益合计

4,493

4,493

4,215

4,215

Total liabilities and stockholders’ equity

总负债和股东权益

$

$

15,513

15,513

$

$

14,892

14,892

MOLINA HEALTHCARE, INC.

MOLINA医疗保健公司。

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

未经审计的简明合并现金流量表

Three Months Ended

截至三个月

March 31,

3月31日，

2024

2024

2023

2023

(In millions)

（单位：百万）

Operating activities:

经营活动：

Net income

净收入

$

$

301

301

$

$

321

321

Adjustments to reconcile net income to net cash provided by operating activities:

将净收入调整为经营活动产生的净现金：

Depreciation and amortization

折旧和摊销

45

45

44

44

Deferred income taxes

递延所得税

26

26

1

1

Share-based compensation

股份制薪酬

36

36

25

25

Other, net

其他，净额

2

2

5

5

Changes in operating assets and liabilities:

经营资产和负债的变化：

Receivables

应收账款

(123

(123

)

)

(234

(234

)

)

Prepaid expenses and other current assets

预付费用和其他流动资产

8

8

7

7

Medical claims and benefits payable

应付医疗索赔和福利

(24

(24

)

)

296

296

Amounts due government agencies

应付政府机构款项

183

183

270

270

Accounts payable, accrued liabilities and other

应付账款、应计负债和其他

(215

(215

)

)

(215

(215

)

)

Deferred revenue

递延收入

(90

(90

)

)

295

295

Income taxes

所得税

65

65

101

101

Net cash provided by operating activities

经营活动产生的现金净额

214

214

916

916

Investing activities:

投资活动：

Purchases of investments

购买投资

(380

(380

)

)

(646

(646

)

)

Proceeds from sales and maturities of investments

销售收入和投资到期

211

211

371

371

Net cash paid in business combinations

企业合并支付的现金净额

(295

(295

)

)

—

—

Purchases of property, equipment, and capitalized software

购买财产、设备和资本化软件

(27

(27

)

)

(32

(32

)

)

Other, net

其他，净额

3

3

5

5

Net cash used in investing activities

用于投资活动的现金净额

(488

(488

)

)

(302

(302

)

)

Financing activities:

融资活动：

Common stock withheld to settle employee tax obligations

为解决员工纳税义务而代扣的普通股

(56

(56

)

)

(58

(58

)

)

Other, net

其他，净额

(6

(6

)

)

(7

(7

)

)

Net cash used in financing activities

用于融资活动的现金净额

(62

(62

)

)

(65

(65

)

)

Net (decrease) increase in cash, cash equivalents, and restricted cash and cash equivalents

现金、现金等价物、受限现金和现金等价物净（减少）增加额

(336

(336

)

)

549

549

Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period

期初现金、现金等价物和受限现金及现金等价物

4,908

4,908

4,048

4,048

Cash, cash equivalents, and restricted cash and cash equivalents at end of period

期末现金、现金等价物和受限现金及现金等价物

$

$

4,572

4,572

$

$

4,597

4,597

MOLINA HEALTHCARE, INC.

MOLINA医疗保健公司。

UNAUDITED SEGMENT DATA

未经审计的分部数据

(Dollars in millions)

（百万美元）

March 31,

3月31日，

December 31,

12月31日，

March 31,

3月31日，

2024

2024

2023

2023

2023

2023

Ending Membership by Segment:

按细分市场结束成员资格：

Medicaid

医疗补助

5,123,000

5,123,000

4,542,000

4,542,000

4,834,000

4,834,000

Medicare

医疗保险

258,000

258,000

172,000

172,000

161,000

161,000

Marketplace

市场

346,000

346,000

281,000

281,000

271,000

271,000

Total

总计

5,727,000

5,727,000

4,995,000

4,995,000

5,266,000

5,266,000

Three Months Ended March 31,

截至3月31日的三个月，

2024

2024

2023

2023

Premium

保险费

Revenue

收入

Medical

医疗

Margin

保证金

MCR (1)

MCR（1）

Premium

保险费

Revenue

收入

Medical

医疗

Margin

保证金

MCR (1)

MCR（1）

Medicaid

医疗补助

$

$

7,492

7,492

$

$

775

775

89.7

89.7

%

%

$

$

6,349

6,349

$

$

734

734

88.4

88.4

%

%

Medicare

1,442

163

163

88.7

88.7

1,046

1,046

126

126

88.0

88.0

Marketplace

市场

570

570

152

152

73.3

73.3

490

490

154

154

68.6

68.6

Consolidated

合并

$

$

9,504

9,504

$

$

1,090

1,090

88.5

88.5

%

%

$

$

7,885

7,885

$

$

1,014

1,014

87.1

87.1

%

%

(1) The MCR represents medical costs as a percentage of premium revenue.

（1） MCR表示医疗费用占保费收入的百分比。

MOLINA HEALTHCARE, INC.

MOLINA医疗保健公司。

CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE

应付医疗索赔和福利的变化

(Dollars in millions)

（百万美元）

The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims.

公司的索赔责任包括额外准备金，以根据历史经验和其他因素（包括但不限于索赔支付模式的变化、利用率和成本趋势的变化、已知的疾病爆发以及大额索赔）来解释中度不利条件。

The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported.

本公司的准备金方法在所有列报期间均得到一致应用。“与上一年相关的医疗费用组成部分”显示的金额代表年初应付索赔和福利的原始估计数超过自首次报告这些负债以来根据信息（主要是索赔付款）开发的实际负债的金额。

The following table presents the components of the change in medical claims and benefits payable for the periods indicated:.

下表列出了所示期间应付医疗索赔和福利变动的组成部分：。

Three Months Ended

截至三个月

March 31,

3月31日，

2024

2024

2023

2023

Unaudited

未经审计

Medical claims and benefits payable, beginning balance

应付医疗索赔和福利，期初余额

$

$

4,204

4,204

$

$

3,528

3,528

Components of medical care costs related to:

医疗保健费用的组成部分涉及：

Current year

本年度

8,748

8,748

7,169

7,169

Prior year

上一年

(334

(334

)

)

(298

(298

)

)

Total medical care costs

医疗保健总费用

8,414

8,414

6,871

6,871

Payments for medical care costs related to:

支付与以下相关的医疗费用：

Current year

本年度

5,409

5,409

4,487

4,487

Prior year

上一年

2,879

2,879

2,358

2,358

Total paid

已付总额

8,288

8,288

6,845

6,845

Acquired balances, net of post-acquisition adjustments

收购后余额，扣除收购后调整

391

391

—

—

Change in non-risk and other payables

非风险和其他应付款的变化

(150

(150

)

)

270

270

Medical claims and benefits payable, ending balance

应付医疗索赔和福利，期末余额

$

$

4,571

4,571

$

$

3,824

3,824

Days in Claims Payable (1)

应付索赔天数（1）

49

49

48

48

__________________

__________________

(1)

(1)

The Company calculates Days in Claims Payable using claims incurred but not paid, or IBNP, and other fee-for-service payables included in medical claims and benefits payable, and quarterly fee-for-service related costs included in medical care costs within the Company’s consolidated financial statements..

公司使用已发生但未支付的索赔或IBNP，以及包括在医疗索赔和应付福利中的其他应付服务费，以及包括在公司合并财务报表中的医疗保健成本中的季度服务费相关成本来计算应付索赔天数。。

MOLINA HEALTHCARE, INC.

MOLINA医疗保健公司。

RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES

未经审计的非公认会计准则财务指标的对账

(In millions, except per diluted share amounts)

（单位：百万，稀释后每股金额除外）

The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time.

该公司认为，某些非公认会计原则（公认会计原则）财务指标是投资者将公司业绩与医疗保健行业其他上市公司业绩进行比较的有用补充指标。非GAAP财务指标也在内部使用，以使管理层能够随着时间的推移持续评估公司的业绩。

These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures..

下面列出的这些非公认会计准则财务指标应被视为对公认会计准则指标的补充，而不是替代或优于公认会计准则指标。。

Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations..

调整代表GAAP净收入的增加和减少，如下表所示，其中包括收购无形资产摊销的非现金影响、收购相关费用以及管理层认为不代表长期业务趋势和运营的某些费用和其他项目的影响。。

Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.

调整后的G＆A比率代表公认会计准则G＆A比率，确认调整。

Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.

调整后的净收入代表确认调整后的GAAP净收入（税后）。公司认为，调整后的净收益有助于投资者评估公司的财务业绩。

Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.

调整后的稀释每股净收入是指调整后的净收入除以在完全稀释基础上发行的加权平均普通股。

Adjusted after-tax margin represents adjusted net income, divided by total revenue.

调整后的税后利润率代表调整后的净收入除以总收入。

Three Months Ended March 31,

截至3月31日的三个月，

2024

2024

2023

2023

Amount

金额

Per Diluted

每稀释

Share

分享

Amount

金额

Per Diluted

每稀释

Share

分享

GAAP Net income

GAAP净收入

$

$

301

301

$

$

5.17

5.17

$

$

321

321

$

$

5.52

5.52

Adjustments:

调整：

Amortization of intangible assets

无形资产摊销

$

$

20

20

$

$

0.35

0.35

$

$

21

21

$

$

0.38

0.38

Acquisition-related expenses (1)

收购相关费用（1）

17

17

0.29

0.29

—

—

—

—

Other (2)

其他（2）

6

6

0.10

0.10

—

—

—

—

Subtotal, adjustments

小计，调整

43

43

0.74

0.74

21

21

0.38

0.38

Income tax effect

所得税影响

(10

(10

)

)

(0.18

(0.18

)

)

(5

(5

)

)

(0.09

(0.09

)

)

Adjustments, net of tax

调整，税后净额

33

33

0.56

0.56

16

16

0.29

0.29

Adjusted net income

调整后净收入

$

$

334

334

$

$

5.73

5.73

$

$

337

337

$

$

5.81

5.81

__________________

__________________

(1)

(1)

Reflects non-recurring costs associated with acquisitions, including various transaction and certain integration costs.

反映与收购相关的非经常性成本，包括各种交易和某些整合成本。

(2)

(2)

The three months ended March 31, 2024 includes non-recurring litigation costs and one-time termination benefits.

截至2024年3月31日的三个月包括非经常性诉讼费用和一次性解雇福利。

MOLINA HEALTHCARE, INC.

MOLINA医疗保健公司。

RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED)

未经审计的非公认会计准则财务指标的对账（续）

2024 GUIDANCE

2024年指南

Amount

金额

Per

每

Diluted

稀释

Share (2)

共享（2）

GAAP Net income

GAAP净收入

$

$

1,266

1,266

$

$

21.79

21.79

Adjustments:

调整：

Amortization of intangible assets

无形资产摊销

92

92

1.57

1.57

Acquisition-related expenses

收购相关费用

33

33

0.58

0.58

Other

其他

6

6

0.10

0.10

Subtotal, adjustments

小计，调整

131

131

2.25

2.25

Income tax effect (1)

所得税影响（1）

(31

(31

)

)

(0.54

(0.54

)

)

Adjustments, net of tax

调整，税后净额

100

100

1.71

1.71

Adjusted net income

调整后净收入

$

$

1,366

1,366

$

$

23.50

23.50

__________________

__________________

(1)

(1)

Income tax effect calculated at the statutory tax rate of approximately 23.9%.

所得税影响按约23.9%的法定税率计算。

(2)

(2)

Computations assume approximately 58.1 million diluted weighted average shares outstanding.

计算假设约5810万股稀释加权平均流通股。